Search

23 Feb 2024: A complex autoimmune disease, lupus affects approximately five million people worldwide, primarily women. ... Potential for Personalized Treatment. Dr. Smith's group has discovered that lupus patients who develop more severe disease have a distinctive

2 Nov 2021: The majority of patients were from the UK (96%) and had inflammatory arthritis (32%) or lupus (32%). ... There was concern, too, that telemedicine increased the potential for inequalities in treatment.

23 Feb 2024: Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

23 Feb 2024: Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. ... Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

19 Feb 2024: u/u/p pemI feel that she [/emrheumatologistem] doesn’t care about me and so I no longer care about my lupus treatment and medication either. ... fatigue, pain, cognitive impairment and others, have received very limited support, treatment or

New drug Benlysta in Lupus treatment. ... Published on. 15 June, 2011. “Benlysta emerges as a direct approach in lupus treatment.

Human antibody approved for treatment of lupus. ... Published on. 11 March, 2011. Systemic lupus erythematosus is a chronic, life-threatening inflammatory autoimmune disease that can cause debilitating fatigue, painful and swollen joints, fever, skin rash

2022: Fellow Prof. Rahul Roychoudhuri signs a partnership with AstraZeneca to advance the treatment of lupus.

Yonath (Weizmann Institute of Science, Israel). The trio showed how the information encoded on strands of DNA […]. Human Antibodies developed for Treatment of Lupus and Anthrax. ... treat lupus, a potentially fatal autoimmune disease, and anthrax, a

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

{"id":4193,"date":"2013-01-07T13:50:34","date_gmt":"2013-01-07T13:50:34","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/research/technology-transfer/history-of-technology-transfer/"},"modified":"2023-07-21T12:49:41","modified_gmt":"2023-

19 Feb 2024: u/u/p pemI feel that she [/emrheumatologistem] doesn’t care about me and so I no longer care about my lupus treatment and medication either. ... of Cambridge to study the experiences of patients with lupus and related diseases.

19 Feb 2024: u/u/p pemI feel that she [/emrheumatologistem] doesn’t care about me and so I no longer care about my lupus treatment and medication either. ... of Cambridge to study the experiences of patients with lupus and related diseases.

19 Feb 2024: p pThere was concern, too, that telemedicine increased the potential for inequalities in treatment. ... u/u/p pemI feel that she [/emrheumatologistem] doesn’t care about me and so I no longer care about my lupus treatment and medication either.

23 Feb 2024: The MASTERPLANS team will work to identify factors that predict which patients respond well on any particular lupus treatment. ... Sample tissue, blood and urine from patients with skin or renal lupus will be used to identify biological predictors that

19 Feb 2024: psychiatric symptoms amongst 1,853 patients with systemic auto-immune rheumatic diseases (SARDs) such as lupus and rheumatoid arthritis. ... u/u/p pemI feel that she [/emrheumatologistem] doesn’t care about me and so I no longer care about my lupus

21 Jul 2023: This antibody, for treatment of rheumatoid arthritis, proved a blockbuster drug with total sales of more than $10 billion by the end of 2009. ... Other antibodies followed, including BENLYSTA, which promises to be the first new drug treatment for

23 Feb 2024: treatment. Many patients described how their reported symptoms were treated as less important than blood test results (which can be misleading in lupus-related conditions) and said the listening skills of ... I feel that she [rheumatologist] doesn’t